Furthermore, cibisatamab treatment frequently triggered the relocalization of the CD8 + T cells from the stroma to the tumour beds, resulting in the conversion of immune-excluded tumours (in which the CD8 T cells are primarily in the tumour stroma) to inflamed tumours (in which the CD8 T cells are infiltrating the tumour nests) (Fig. 5F). This evidence concerns the gene CD8A and neoplasm.